Core Viewpoint - The Chinese cosmetics industry is still in an upward cycle in 2025, but the upstream supply chain is experiencing a phenomenon of "increased revenue without increased profit" [3][4]. Group 1: Industry Growth and Challenges - The cosmetics ODM industry is witnessing significant growth, with leading companies like Cosmax and Babi achieving revenue growth rates exceeding 10%, and Babi's annual revenue growth surpassing 20% [3][6]. - Despite the revenue growth, profit growth among ODM companies in the Chinese market is showing signs of fatigue, with some companies experiencing profit declines and relying on asset sales to boost profit levels [3][8]. - The demand for ODM in the beauty industry is accelerating towards concentration, reflected in the rapid growth of leading ODM companies [5]. Group 2: Competitive Landscape and Financial Pressures - The changing beauty consumption landscape is creating more structural growth opportunities, with ODM companies betting on high-performance makeup and refined skincare in emerging markets [7]. - Intense competition is leading to financial pressures for ODM companies, as brand clients are forced to invest more in traffic, which in turn compresses prices and profit margins for suppliers [7][8]. - Babi's financial report indicates a net profit of 38.74 million yuan in 2025, down 14.64% year-on-year, attributed to increased market competition and strategic investments [8][25]. Group 3: Strategic Shifts in ODM Operations - The growth logic of the beauty ODM industry is shifting from "scale for profit" to a focus on high-quality development, with low-quality capacity being eliminated [10][11]. - Successful ODM companies are increasingly relying on deep collaborations with major clients, emphasizing research and development to enhance product market efficiency [11][12]. - Babi's long-term partnerships with major brands have led to the development of popular products, showcasing the importance of deep collaboration in driving growth [12][14]. Group 4: Investment in Research and Development - ODM companies are investing in R&D to enhance product competitiveness, with Babi's R&D expenses reaching 14.49 million yuan in the first half of 2025, a year-on-year increase of 8.02% [16][26]. - Babi has accumulated 145 authorized patents and developed over 130 proprietary raw materials, indicating a strong commitment to innovation [17][18]. - The focus on R&D is expected to pay off in the long term, as companies that invest in high-quality products and research will have a competitive edge in the evolving market [22][24]. Group 5: Global Expansion and Future Opportunities - Chinese ODM companies are increasingly gaining international clients due to better cost control and production efficiency, with Babi exporting products to over 30 countries [31][32]. - The shift from "order-based" to "coexistence-based" collaboration between brands and ODM companies is anticipated, allowing for higher quality growth and global supply chain integration [32]. - The long-term strategic investments in R&D and market expansion are expected to reshape the competitive landscape of the industry, positioning high-quality ODM companies favorably for future growth [30][32].

Core Insights - The beauty ODM industry in China is facing dual pressures in 2025: price squeeze from the market and the need for transformation towards high-quality growth [2] - The industry is accelerating the elimination of outdated production capacity, with 1,318 companies shut down or deregistered in 2024, while only 542 new cosmetic production companies were registered in 2025 [2] - Companies that embrace high-quality development and move away from traditional bidding models are being rewarded by the market, as exemplified by the leading ODM company, Norsbel, which is expected to achieve revenue exceeding 2.2 billion yuan in 2025 [3][4] Industry Trends - The Chinese cosmetics market is undergoing a deep adjustment period characterized by stock competition and value return, with consumers increasingly prioritizing product quality, efficacy, and safety over cost [4] - Norsbel has diversified its client base, serving both international giants like Procter & Gamble and L'Oréal, as well as emerging brands, adapting to the changing demands for faster market response and localized innovation [6][7] - The competition focus is shifting from price to quality and technology, compelling the supply chain to innovate continuously to create core value [7] Company Strategy - Norsbel's growth in 2025 is attributed to its strategic focus on customer and product, achieving quality internal growth through meticulous efforts in R&D, market development, cost control, and human resource management [8] - The company has invested over 80 million yuan annually in R&D over the past three years, establishing a professional team of over 180 people and introducing 777 new raw materials in 2025 [8][9] - Norsbel is transitioning from a production service provider to a long-term technical partner, emphasizing the importance of research and innovation to enhance its comprehensive competitiveness [9] Technological Innovation - Digitalization is a key driver for Norsbel's efficiency, with over 82% of its smart factory's equipment being digitalized, supporting rapid market response and flexible supply [10] - The company has implemented AI technology in R&D and production processes, optimizing formula development and enhancing production efficiency [10] - Norsbel has developed an industry-first AI model for mask appearance detection, integrating machine vision and deep learning for high-precision quality control [10] Future Outlook - Norsbel aims to play a pivotal role in the global beauty innovation landscape, focusing on sustainable value creation through technological innovation and efficiency [19][20] - The company is positioned to leverage the globalization of Chinese technology, aiming to be a long-distance runner rather than a sprinter in the competitive landscape [20] - Norsbel's strategic roles include being a promoter of Chinese innovation, a connector of global beauty innovation, and a leader in industry standards [25][26]

Group 1: Institutional Trading Insights - A total of 39 stocks were listed on the institutional trading leaderboard, with 20 stocks experiencing net buying and 19 stocks facing net selling [1] - The top three stocks with the highest net buying by institutions were: Hite Bio (¥138 million), Tianshan Shares (¥60.08 million), and Shangfeng Cement (¥53.09 million) [1] Group 2: Stock Performance - Hite Bio (300683.SZ) saw a price increase of 7.18% with 5 buyers and 4 sellers [2] - Tianshan Shares (000877.SZ) experienced a decline of 6.27% with 3 buyers and no sellers [2] - Shangfeng Cement (000672.SZ) had a significant drop of 9.27% with 2 buyers and no sellers [2] Group 3: Company Highlights - Hite Bio's main product, Jinlujie (injectable mouse nerve growth factor), is the first government-approved drug for nerve injury-related diseases globally [3] - China Electric Power Construction Corporation is the largest contractor and designer for water conservancy and hydropower projects, handling 80% of large hydropower station design and construction in China [4] - The company holds a 34% stake in the Tibet Southeast Clean Energy Development Company, creating a closed loop of "design - construction - operation" [4] Group 4: Market Trends - The opening of the Yarlung Tsangpo River downstream hydropower project has garnered significant market attention, benefiting infrastructure stocks through increased demand and valuation recovery [4] - Two categories of companies are expected to benefit: those directly involved in major engineering projects and low-valuation, high-dividend construction leaders [4] Group 5: Health Sector Update - A cosmetics ODM service provider has obtained production licenses for mosquito repellent products amid warnings from the World Health Organization regarding the chikungunya virus [6] - The WHO has raised alerts about the chikungunya virus, which is transmitted by infected mosquitoes, emphasizing the need for preventive measures [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is positioned as a leading player in the ODM (Original Design Manufacturer) sector for skincare products, with significant growth potential driven by R&D and testing capabilities, as well as expanding overseas markets [1][4] - The company has demonstrated strong revenue growth, with a 48.27% year-on-year increase in revenue for 2024 and a 40.15% increase in Q1 2025 [3][4] - The company is focusing on a "big client, big product" strategy to enhance service quality and product value, which is expected to drive market share growth domestically and internationally [4] Financial Performance Summary - In 2024, the company achieved revenue of 6.95 billion yuan, a 48.27% increase year-on-year, and a net profit of 453.9 million yuan, a 10.28% increase [3] - For Q1 2025, the company reported revenue of 1.62 billion yuan, a 40.15% increase year-on-year, and a net profit of 8.62 million yuan, an 8.81% increase [3] - The company’s revenue projections for 2025, 2026, and 2027 are 9.66 billion yuan, 11.21 billion yuan, and 12.85 billion yuan respectively, with year-on-year growth rates of 39.0%, 16.1%, and 14.6% [5] - The projected net profit for 2025, 2026, and 2027 is 610 million yuan, 800 million yuan, and 1.01 billion yuan respectively, with corresponding EPS of 0.54, 0.72, and 0.91 yuan per share [5] Product and Market Insights - The company’s main product categories, including skincare (excluding masks), masks, and hair care, have shown significant revenue growth, with skincare revenue increasing by 49.56% year-on-year [4] - The company has successfully registered new raw materials with the National Medical Products Administration, which is expected to enhance its product offerings [4] - The overseas revenue for 2024 reached 526.29 million yuan, a remarkable 361.52% increase year-on-year, indicating strong international market potential [4]